---
title: "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294685292.md"
description: "In the second quarter of 2026, the global revenue reached around $240 million, with BRIUMVI U.S. net product revenue contributing about $228 million to this total."
datetime: "2026-08-03T11:03:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294685292.md)
  - [en](https://longbridge.com/en/news/294685292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294685292.md)
---

# TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

In the second quarter of 2026, the global revenue reached around $240 million, with BRIUMVI U.S. net product revenue contributing about $228 million to this total.

### Related Stocks

- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)

## Related News & Research

- [TGTX: Record BRIUMVI growth and raised guidance highlight a strong quarter and expanding franchise](https://longbridge.com/en/news/294709467.md)
- [Tredegar (NYSE:TG) Insider Arijit Dasgupta Acquires 2,093 Shares of Stock](https://longbridge.com/en/news/296278499.md)
- [Tredegar (NYSE:TG) Major Shareholder William Gottwald Sells 7,718 Shares](https://longbridge.com/en/news/296383737.md)
- [Insider Selling: Tredegar (NYSE:TG) Major Shareholder Sells $27,810.72 in Stock](https://longbridge.com/en/news/296383723.md)
- [A Historic First: Boréalys Mont-Tremblant by UTMB® Kicks Off Tomorrow](https://longbridge.com/en/news/295779979.md)